Efficacy and Safety of Pimavanserin for Treating Dementia-Related Psychosis in Lewy Body Dementia Patients: Insights from the HARMONY Trial - Takeaways - MDSpire

Efficacy and Safety of Pimavanserin for Treating Dementia-Related Psychosis in Lewy Body Dementia Patients: Insights from the HARMONY Trial

  • By

  • Yasar Torres-Yaghi

  • Lambros Chrones

  • Victor Abler

  • Greg Brunson

  • November 24, 2025

  • 0 min

Share

  • 1

    Pimavanserin is the only FDA-approved treatment for hallucinations and delusions in Parkinson’s disease psychosis.

  • 2

    The HARMONY trial evaluated pimavanserin's efficacy and safety in patients with dementia-related psychosis, including Lewy body dementia.

  • 3

    The trial was stopped early for efficacy, indicating significant benefits of pimavanserin in reducing psychosis relapse.

  • 4

    Patients receiving pimavanserin showed a lower risk of relapse compared to those who discontinued the treatment.

  • 5

    The study adhered to ethical standards and included comprehensive assessments of safety and cognitive function.

Original Source(s)

Efficacy and Safety of Pimavanserin for Treating Dementia-Related Psychosis in Lewy Body Dementia Patients: Insights from the HARMONY Trial

  • by Yasar Torres-Yaghi, Lambros Chrones, Victor Abler, Greg Brunson

  • November 24, 2025

Related Content

A homozygous missense variant, p.Ser166Leu in the PRPF40B gene, in a 7.7 Mb region of homozygosity in a consanguineous Turkish family with essential tremor

A multimodal machine learning model for predicting postoperative worsening of FOGQ in Parkinson’s disease following STN-DBS

Cognitive impairment and associated factors in elderly patients with schizophrenia: a retrospective observational study with phenotype analysis